Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate

Acepodia received FDA clearance to initiate a Phase 1 clinical trial, enabling the first AD2C-generated candidate to move into clinical development. The update is a meaningful regulatory and technical milestone for the company’s pipeline, but it does not yet include efficacy or commercial-impact data. Overall, it’s supportive for sentiment toward near-term clinical progress.